ANCHOR LEAD: WOULD ADDITIONAL GROUPS OF PEOPLE BENEFIT FROM STATINS? ELIZABETH TRACEY REPORTS
Jupiter is the acronym for a recently reported cardiovascular disease study. Erin Michos, a cardiologist at Johns Hopkins who was not involved in this study, has extrapolated the Jupiter trial results to conclude that many, many more people may be eligible and likely benefit from statin therapy than are currently.
MICHOS: Using all those exclusion inclusion criteria we found that 6.5 million older adults in the United States would be newly eligible for statins that would previously not have been eligible for statins on the basis of having a low or normal LDL cholesterol. And specifically, the JUPITER thresholds was an LDL less than 130 and a C-reactive protein greater than 2 milligrams per liter. :25
Modifying both cholesterol profile and reducing C-reactive protein levels has been shown to result in fewer cardiovascular events, and statins are generally effective at doing so. At Johns Hopkins, I’m Elizabeth Tracey.